The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a retroviral vector expressing a receptor compoent comprising a scFv of anti-CD19 antibody linked to RXR, and a signaling component comprising EcR linked to CD3ζ signaling domain. The activation of conditional CAR can be controlled by RXR-EcR dimerization using RSL1. And the vector product was designed for the treatment of chronic lymphoid leukemia.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|CAR-LC232||Anti-CD19 (S2) h(41BB-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC638||Lenti-CD19 CAR (scFv-41BB-CD3ζ, CTL019) Viral Particle|
|CAR-MZ130||Anti-CD19 (SJ25C1) h(OX-40-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC704||Lenti-CD19 CAR (scFv-41BB-CD3ζ, S2) Viral Particle|
|CAR-LC225||Anti-CD19 h(CD2-CD3ζ) CAR, pCDCAR1|
|CAR-MZ052||Anti-CD19 scFv h(41BB-CD28-CD3ζ) CAR, pCDCAR1|
|CAR-LC298||Anti-CD19 (4G7) h(41BB) Multi-chain CAR, pCDCAR1|
|CAR-LC186||Anti-CD19 (Coltuximab) h(41BB-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC749||Lenti-CD19 CAR (scFv-CD28-CD3ζ, 1D3) Viral Particle|
|CAR-T-1-L332-G||Anti-CD19 scFv h(FcεRIγ) CART, pCDCAR1|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved